Theriva Biologics, Inc.
TOVX
$1.42
$0.00780.55%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.90M | 7.07M | 7.17M | 7.68M | 7.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.93M | 20.41M | 21.78M | 22.48M | 22.26M |
| Operating Income | -18.93M | -20.41M | -21.78M | -22.48M | -22.26M |
| Income Before Tax | -25.65M | -27.12M | -23.22M | -20.35M | -19.99M |
| Income Tax Expenses | -- | -424.00K | -951.00K | -1.31M | -1.64M |
| Earnings from Continuing Operations | -25.65 | -26.69 | -22.27 | -19.04 | -18.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.65M | -26.69M | -22.27M | -19.04M | -18.35M |
| EBIT | -18.93M | -20.41M | -21.78M | -22.48M | -22.26M |
| EBITDA | -18.79M | -20.27M | -21.64M | -22.33M | -22.13M |
| EPS Basic | -26.65 | -33.09 | -31.13 | -28.79 | -28.66 |
| Normalized Basic EPS | -11.67 | -15.81 | -18.43 | -19.94 | -20.21 |
| EPS Diluted | -26.65 | -33.09 | -31.13 | -28.79 | -28.66 |
| Normalized Diluted EPS | -11.67 | -15.81 | -18.43 | -19.94 | -20.21 |
| Average Basic Shares Outstanding | 5.39M | 3.28M | 2.83M | 2.66M | 2.58M |
| Average Diluted Shares Outstanding | 5.39M | 3.28M | 2.83M | 2.66M | 2.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |